<DOC>
	<DOCNO>NCT00738530</DOCNO>
	<brief_summary>This 2-arm study evaluate efficacy safety Avastin versus placebo combination Roferon first-line treatment participant metastatic renal cell cancer ( clear cell type ) nephrectomy . The anticipated time study treatment 1-2 year , target sample size great ( &gt; ) 500 individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Added Interferon Alfa-2a ( Roferon ) Therapy Patients With Metastatic Renal Cell Cancer With Nephrectomy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>metastatic renal cell cancer ( clear cell type ) ; nephrectomy ; absence proteinuria . prior systemic treatment metastatic renal cell cancer ; major surgical procedure , open biopsy significant traumatic injury within 28 day prior study treatment start ; presence brain metastasis spinal cord compression ; ongoing need full dose anticoagulant ; uncontrolled hypertension ; clinically significant cardiovascular disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>